A detailed history of Lindbrook Capital, LLC transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Lindbrook Capital, LLC holds 63 shares of LGND stock, worth $7,049. This represents 0.0% of its overall portfolio holdings.

Number of Shares
63
Previous 63 -0.0%
Holding current value
$7,049
Previous $5,000 20.0%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

BUY
$68.53 - $87.91 $548 - $703
8 Added 14.55%
63 $5,000
Q4 2023

Jan 31, 2024

BUY
$49.57 - $72.63 $2,726 - $3,994
55 New
55 $3,000
Q1 2023

Apr 26, 2023

BUY
$65.67 - $77.08 $1,313 - $1,541
20 New
20 $1,000
Q3 2022

Nov 10, 2022

BUY
$0.01 - $107.56 $0 - $6,238
58 New
58 $5,000
Q2 2020

Jul 27, 2020

SELL
$68.28 - $123.65 $1,297 - $2,349
-19 Closed
0 $0
Q3 2019

Oct 31, 2019

SELL
$86.25 - $120.16 $4,916 - $6,849
-57 Reduced 75.0%
19 $2,000
Q4 2018

Feb 07, 2019

BUY
$128.36 - $272.13 $9,755 - $20,681
76 New
76 $10,000

Others Institutions Holding LGND

About LIGAND PHARMACEUTICALS INC


  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $1.89B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Lindbrook Capital, LLC Portfolio

Follow Lindbrook Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.